BENDSZUS, Martin, Jens FIEHLER, Fabien SUBTIL, Susanne BONEKAMP, Anne Hege AAMODT, Blanca FUENTES, Elke R GIZEWSKI, Michael D HILL, Antonin KRAJINA, Laurent PIEROT, Claus Z SIMONSEN, Kamil ZELENAK, Rolf A BLAUENFELDT, Bastian CHENG, Angelique DENIS, Hannes DEUTSCHMANN, Franziska DORN, Fabian FLOTTMANN, Susanne GELLISSEN, Johannes C GERBER, Mayank GOYAL, Jozef HARING, Christian HERWEH, Silke HOPF-JENSEN, Vi Tuan HUA, Maerit JENSEN, Andreas KASTRUP, Christiane Fee KEIL, Andrej KLEPANEC, Egon KURCA, Ronni MIKKELSEN, Markus MOEHLENBRUCH, Stefan MUELLER-HUELSBECK, Nico MUENNICH, Paolo PAGANO, Panagiotis PAPANAGIOTOU, Gabor C PETZOLD, Mirko PHAM, Volker PUETZ, Jan RAUPACH, Gernot REIMANN, Peter Arthur RINGLEB, Maximilian SCHELL, Eckhard SCHLEMM, Silvia SCHOENENBERGER, Bjorn TENNOE, Christian ULFERT, Kateřina VALIŠ, Eva VITKOVA, Dominik F VOLLHERBST, Wolfgang WICK and Goetz THOMALLA. Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomised trial (Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomised trial. Lancet. 2023 Oct 10:S0140-). Lancet. NEW YORK: ELSEVIER SCIENCE INC, 2023, vol. 402, No 10414, p. 1753-1763. ISSN 0140-6736. Available from: https://dx.doi.org/10.1016/S0140-6736(23)02032-9.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomised trial
Authors BENDSZUS, Martin, Jens FIEHLER, Fabien SUBTIL, Susanne BONEKAMP, Anne Hege AAMODT, Blanca FUENTES, Elke R GIZEWSKI, Michael D HILL, Antonin KRAJINA, Laurent PIEROT, Claus Z SIMONSEN, Kamil ZELENAK, Rolf A BLAUENFELDT, Bastian CHENG, Angelique DENIS, Hannes DEUTSCHMANN, Franziska DORN, Fabian FLOTTMANN, Susanne GELLISSEN, Johannes C GERBER, Mayank GOYAL, Jozef HARING, Christian HERWEH, Silke HOPF-JENSEN, Vi Tuan HUA, Maerit JENSEN, Andreas KASTRUP, Christiane Fee KEIL, Andrej KLEPANEC, Egon KURCA, Ronni MIKKELSEN, Markus MOEHLENBRUCH, Stefan MUELLER-HUELSBECK, Nico MUENNICH, Paolo PAGANO, Panagiotis PAPANAGIOTOU, Gabor C PETZOLD, Mirko PHAM, Volker PUETZ, Jan RAUPACH, Gernot REIMANN, Peter Arthur RINGLEB, Maximilian SCHELL, Eckhard SCHLEMM, Silvia SCHOENENBERGER, Bjorn TENNOE, Christian ULFERT, Kateřina VALIŠ (203 Czech Republic), Eva VITKOVA, Dominik F VOLLHERBST, Wolfgang WICK and Goetz THOMALLA.
Edition Lancet, NEW YORK, ELSEVIER SCIENCE INC, 2023, 0140-6736.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30230 Other clinical medicine subjects
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW TENSION
Impact factor Impact factor: 168.900 in 2022
RIV identification code RIV/00216224:90249/23:00131960
Doi http://dx.doi.org/10.1016/S0140-6736(23)02032-9
UT WoS 001116664800001
Keywords (in Czech) METAANALYSIS; THERAPY; TENSION
Keywords in English METAANALYSIS; THERAPY; TENSION
Tags Excelence Science, MU, neMU, RIV, user, článek v časopise
Tags International impact, Reviewed
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 12/4/2024 12:59.
Abstract
Background Recent evidence suggests a beneficial effect of endovascular thrombectomy in acute ischaemic stroke with large infarct; however, previous trials have relied on multimodal brain imaging, whereas non-contrast CT is mostly used in clinical practice. Methods In a prospective multicentre, open-label, randomised trial, patients with acute ischaemic stroke due to large vessel occlusion in the anterior circulation and a large established infarct indicated by an Alberta Stroke Program Early Computed Tomographic Score (ASPECTS) of 3-5 were randomly assigned using a central, web-based system (using a 1:1 ratio) to receive either endovascular thrombectomy with medical treatment or medical treatment (ie, standard of care) alone up to 12 h from stroke onset. The study was conducted in 40 hospitals in Europe and one site in Canada. The primary outcome was functional outcome across the entire range of the modified Rankin Scale at 90 days, assessed by investigators masked to treatment assignment. The primary analysis was done in the intention-to-treat population. Safety endpoints included mortality and rates of symptomatic intracranial haemorrhage and were analysed in the safety population, which included all patients based on the treatment they received. This trial is registered with ClinicalTrials.gov, NCT03094715.Findings From July 17, 2018, to Feb 21, 2023, 253 patients were randomly assigned, with 125 patients assigned to endovascular thrombectomy and 128 to medical treatment alone. The trial was stopped early for efficacy after the first pre-planned interim analysis. At 90 days, endovascular thrombectomy was associated with a shift in the distribution of scores on the modified Rankin Scale towards better outcome (adjusted common OR 2 center dot 58 [95% CI 1 center dot 60-4 center dot 15]; p=0 center dot 0001) and with lower mortality (hazard ratio 0 center dot 67 [95% CI 0 center dot 46-0 center dot 98]; p=0 center dot 038). Symptomatic intracranial haemorrhage occurred in seven (6%) patients with thrombectomy and in six (5%) with medical treatment alone.Interpretation Endovascular thrombectomy was associated with improved functional outcome and lower mortality in patients with acute ischaemic stroke from large vessel occlusion with established large infarct in a setting using non-contrast CT as the predominant imaging modality for patient selection.
Links
90249, large research infrastructuresName: CZECRIN IV
PrintDisplayed: 25/5/2024 10:20